830 WINTER STREET, WALTHAM, MA
Q32 Bio Inc. Enters Controlled Equity Offering Sales Agreement for $14.2M
Financial Results, Press Release
Announces $10.5 Million Registered Direct Offering
Mark Iwicki Withdraws Resignation from Q32 Bio Board of Directors
Sells Complement Inhibitor ADX-097
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement